How much profit has BB Biotech made this year?
BB Biotech has made 195.71 M CHF this year.
BB Biotech Net Income 2024
BB Biotech Net Income
195.71 M CHF
Ticker
BION.SW
ISIN
CH0038389992
WKN
A0NFN3
In 2024, BB Biotech's profit amounted to 195.71 M CHF, a -194.72% increase from the -206.61 M CHF profit recorded in the previous year.
The BB Biotech Net Income history
| YEAR | NET INCOME (undefined CHF) |
|---|---|
| 2026e | 0.24 |
| 2025e | 0.22 |
| 2024e | 0.2 |
| 2023 | -0.21 |
| 2022 | -0.36 |
| 2021 | -0.4 |
| 2020 | 0.69 |
| 2019 | 0.68 |
| 2018 | -0.47 |
| 2017 | 0.69 |
| 2016 | -0.8 |
| 2015 | 0.65 |
| 2014 | 1.47 |
| 2013 | 0.93 |
| 2012 | 0.37 |
| 2011 | -0.07 |
| 2010 | -0.15 |
| 2009 | 0.04 |
| 2008 | 0.05 |
| 2007 | -0.27 |
| 2006 | 0.3 |
| 2005 | 0.32 |
| 2004 | 0.2 |
BB Biotech Revenue, EBIT, Net Income CH0038389992 · A0NFN3
3 years
5 years
10 years
25 Years
Max
Revenue
EBIT
Net Income
Details
Revenue, EBIT and Profit
ⓘUnderstanding Revenue, EBIT, and Income
Gain insights into BB Biotech, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by BB Biotech from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects BB Biotech’s net earnings, an ultimate measure of its financial health and profitability.
Yearly Analysis and Comparisons
Observe the yearly bars to understand the annual performance and growth of BB Biotech. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.
Utilizing Expectations for Investment
The expected values for the forthcoming years offer investors a glimpse into BB Biotech’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.
Investment Insights
Leveraging the comparison between Revenue and EBIT helps in assessing BB Biotech’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on BB Biotech’s growth potential.
BB Biotech Revenue, EBIT and net profit per share
| Date | BB Biotech Revenue | BB Biotech EBIT | BB Biotech Net Income |
|---|---|---|---|
| 2026e | 156.11 M undefined | 200.99 M undefined | 238.28 M undefined |
| 2025e | 136.94 M undefined | 172.13 M undefined | 220.57 M undefined |
| 2024e | 126.99 M undefined | 163.2 M undefined | 195.71 M undefined |
| 2023 | 530,000 undefined | -39.92 M undefined | -206.61 M undefined |
| 2022 | 1.26 M undefined | -43.49 M undefined | -357.81 M undefined |
| 2021 | -343.59 M undefined | -403.78 M undefined | -404.81 M undefined |
| 2020 | 741.78 M undefined | 693.11 M undefined | 691.17 M undefined |
| 2019 | 728.17 M undefined | 678.67 M undefined | 677.43 M undefined |
| 2018 | 5.78 M undefined | -41.64 M undefined | -471.34 M undefined |
| 2017 | 730.05 M undefined | 687.58 M undefined | 687.5 M undefined |
| 2016 | 9.5 M undefined | -28.29 M undefined | -802.07 M undefined |
| 2015 | 697.95 M undefined | 654.23 M undefined | 652.82 M undefined |
| 2014 | 1.5 B undefined | 1.47 B undefined | 1.47 B undefined |
| 2013 | 950.9 M undefined | 932 M undefined | 931.8 M undefined |
| 2012 | 392 M undefined | 368.6 M undefined | 367.8 M undefined |
| 2011 | -47.9 M undefined | -65 M undefined | -65.1 M undefined |
| 2010 | -128.1 M undefined | -143.3 M undefined | -146.3 M undefined |
| 2009 | 53.1 M undefined | 36.3 M undefined | 36.6 M undefined |
| 2008 | 73.8 M undefined | 48.8 M undefined | 45.4 M undefined |
| 2007 | -210.7 M undefined | -264.5 M undefined | -265.4 M undefined |
| 2006 | 318.3 M undefined | 298.2 M undefined | 297.4 M undefined |
| 2005 | 333.3 M undefined | 319.2 M undefined | 318 M undefined |
| 2004 | 213.7 M undefined | 200.8 M undefined | 202.8 M undefined |
| Revenue | EBIT | Net Income | |
|---|---|---|---|
| 2004 | 213.7 M CHF | 200.8 M CHF | 202.8 M CHF |
| 2005 | 333.3 M CHF | 319.2 M CHF | 318 M CHF |
| 2006 | 318.3 M CHF | 298.2 M CHF | 297.4 M CHF |
| 2007 | -210.7 M CHF | -264.5 M CHF | -265.4 M CHF |
| 2008 | 73.8 M CHF | 48.8 M CHF | 45.4 M CHF |
| 2009 | 53.1 M CHF | 36.3 M CHF | 36.6 M CHF |
| 2010 | -128.1 M CHF | -143.3 M CHF | -146.3 M CHF |
| 2011 | -47.9 M CHF | -65 M CHF | -65.1 M CHF |
| 2012 | 392 M CHF | 368.6 M CHF | 367.8 M CHF |
| 2013 | 950.9 M CHF | 932 M CHF | 931.8 M CHF |
| 2014 | 1.5 B CHF | 1.47 B CHF | 1.47 B CHF |
| 2015 | 697.95 M CHF | 654.23 M CHF | 652.82 M CHF |
| 2016 | 9.5 M CHF | -28.29 M CHF | -802.07 M CHF |
| 2017 | 730.05 M CHF | 687.58 M CHF | 687.5 M CHF |
| 2018 | 5.78 M CHF | -41.64 M CHF | -471.34 M CHF |
| 2019 | 728.17 M CHF | 678.67 M CHF | 677.43 M CHF |
| 2020 | 741.78 M CHF | 693.11 M CHF | 691.17 M CHF |
| 2021 | -343.59 M CHF | -403.78 M CHF | -404.81 M CHF |
| 2022 | 1.26 M CHF | -43.49 M CHF | -357.81 M CHF |
| 2023 | 530,000 CHF | -39.92 M CHF | -206.61 M CHF |
| 2024e | 126.99 M CHF | 163.2 M CHF | 195.71 M CHF |
| 2025e | 136.94 M CHF | 172.13 M CHF | 220.57 M CHF |
| 2026e | 156.11 M CHF | 200.99 M CHF | 238.28 M CHF |
BB Biotech stock margins CH0038389992 · A0NFN3
The BB Biotech margin analysis displays the gross margin, EBIT margin, as well as the profit margin of BB Biotech. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for BB Biotech.
3 years
5 years
10 years
25 Years
Max
Gross margin
EBIT margin
Profit margin
Details
Margin
ⓘUnderstanding Gross Margin
The gross margin, expressed as a percentage, delineates the gross profit made from the BB Biotech's sales revenue. A higher gross margin percentage indicates that the BB Biotech retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.
EBIT Margin Analysis
EBIT margin represents the BB Biotech's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.
Revenue Margin Insights
The revenue margin demonstrates the BB Biotech's total revenue generated. When comparing the revenue margin year over year, investors can gauge the BB Biotech's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.
Interpreting Expectations
The expected values for gross, EBIT, and revenue margins provide future financial outlook of the BB Biotech. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.
Comparative Analysis
Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the BB Biotech's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.
BB Biotech Margin History
| BB Biotech Gross margin | BB Biotech Profit margin | BB Biotech EBIT margin | BB Biotech Profit margin |
|---|---|---|---|
| 2026e | -994.72 % | 128.75 % | 152.63 % |
| 2025e | -994.72 % | 125.7 % | 161.07 % |
| 2024e | -994.72 % | 128.51 % | 154.11 % |
| 2023 | -994.72 % | -7,531.13 % | -38,982.46 % |
| 2022 | -36.88 % | -3,448.53 % | -28,375.26 % |
| 2021 | 100.29 % | 117.52 % | 117.82 % |
| 2020 | 99.88 % | 93.44 % | 93.18 % |
| 2019 | 99.83 % | 93.2 % | 93.03 % |
| 2018 | 81.2 % | -720.75 % | -8,158.96 % |
| 2017 | 99.93 % | 94.18 % | 94.17 % |
| 2016 | 88.57 % | -297.88 % | -8,446.35 % |
| 2015 | 99.97 % | 93.74 % | 93.53 % |
| 2014 | 99.96 % | 98.05 % | 98.05 % |
| 2013 | 99.89 % | 98.01 % | 97.99 % |
| 2012 | 99.31 % | 94.03 % | 93.83 % |
| 2011 | 112.94 % | 135.7 % | 135.91 % |
| 2010 | 104.68 % | 111.87 % | 114.21 % |
| 2009 | 89.45 % | 68.36 % | 68.93 % |
| 2008 | 84.55 % | 66.12 % | 61.52 % |
| 2007 | 106.45 % | 125.53 % | 125.96 % |
| 2006 | 98.49 % | 93.69 % | 93.43 % |
| 2005 | 99.97 % | 95.77 % | 95.41 % |
| 2004 | 100 % | 93.96 % | 94.9 % |
| Gross margin | EBIT margin | Profit margin | |
|---|---|---|---|
| 2004 | 100 % | 93.96 % | 94.9 % |
| 2005 | 99.97 % | 95.77 % | 95.41 % |
| 2006 | 98.49 % | 93.69 % | 93.43 % |
| 2007 | 106.45 % | 125.53 % | 125.96 % |
| 2008 | 84.55 % | 66.12 % | 61.52 % |
| 2009 | 89.45 % | 68.36 % | 68.93 % |
| 2010 | 104.68 % | 111.87 % | 114.21 % |
| 2011 | 112.94 % | 135.7 % | 135.91 % |
| 2012 | 99.31 % | 94.03 % | 93.83 % |
| 2013 | 99.89 % | 98.01 % | 97.99 % |
| 2014 | 99.96 % | 98.05 % | 98.05 % |
| 2015 | 99.97 % | 93.74 % | 93.53 % |
| 2016 | 88.57 % | -297.88 % | -8,446.35 % |
| 2017 | 99.93 % | 94.18 % | 94.17 % |
| 2018 | 81.2 % | -720.75 % | -8,158.96 % |
| 2019 | 99.83 % | 93.2 % | 93.03 % |
| 2020 | 99.88 % | 93.44 % | 93.18 % |
| 2021 | 100.29 % | 117.52 % | 117.82 % |
| 2022 | -36.88 % | -3,448.53 % | -28,375.26 % |
| 2023 | -994.72 % | -7,531.13 % | -38,982.46 % |
| 2024e | -994.72 % | 128.51 % | 154.11 % |
| 2025e | -994.72 % | 125.7 % | 161.07 % |
| 2026e | -994.72 % | 128.75 % | 152.63 % |
BB Biotech Aktienanalyse
What does BB Biotech do?
BB Biotech AG is a Swiss investment company specializing in biotechnology and life sciences. The company was founded in 1993 and has been listed on the SIX Swiss Exchange since 1995. BB Biotech AG primarily invests in publicly traded companies in Europe and North America that are active in the biotechnology and healthcare industry. The business model of BB Biotech AG is based on a combination of active portfolio management and long-term investment strategy. The company invests in stocks of biotechnology and healthcare companies that typically do not yet generate profits but are developing promising products or technologies. BB Biotech AG focuses on high portfolio diversification to minimize risk. BB Biotech AG is divided into three business areas: biotechnology, pharmaceuticals, and medtech. The emphasis is on biotechnology, where the company invests in stocks of well-known biotech companies such as Celgene, Gilead Sciences, Regeneron, and Biogen. In the pharmaceutical sector, BB Biotech AG invests in large pharmaceutical companies like Roche, Novartis, or Pfizer. In the medtech sector, the company invests in companies specializing in the development of medical devices and instruments, such as Intuitive Surgical or Neurocrine Biosciences. BB Biotech AG provides added value to its investors through continuous monitoring of the companies in the portfolio and risk management. The company ensures that investors are always informed about the latest developments in the biotechnology and healthcare industry and regularly publishes reports about the portfolio. The portfolio of BB Biotech AG consists of over 30 different biotech, pharmaceutical, and medtech companies. The main holdings of BB Biotech AG are Celgene, Gilead Sciences, Biogen, Incyte, Vertex Pharmaceuticals, Regeneron, and Neurocrine Biosciences. Celgene is one of the world's leading biotech companies specializing in the development of drugs against cancer and other serious diseases. Gilead Sciences is a biotech company specializing in the research of new therapies for the treatment of infectious diseases such as HIV and hepatitis. Biogen is a biotech company specializing in the treatment of neurological disorders such as multiple sclerosis. Incyte is a biotech company specializing in the development of drugs against cancer and inflammatory diseases. Vertex Pharmaceuticals is a biotech company specializing in the treatment of cystic fibrosis. Regeneron is a biotech company specializing in the development of drugs against eye diseases such as macular degeneration and other serious diseases. Neurocrine Biosciences is a medtech company specializing in the development of drugs against sleep disorders and other neurological diseases. BB Biotech AG is an important player in the market for biotechnology and healthcare investments. Through smart selection of investment targets and systematic risk monitoring, the company has enabled investors to achieve high returns with comparatively low risk. Due to these factors, it is now one of the most important holdings in the biotechnology and healthcare sector. BB Biotech ist eines der beliebtesten Unternehmen auf Eulerpool.com.Net Income Details
Understanding BB Biotech's Profit Margins
The profit margins of BB Biotech represent the net income earned after deducting all operational expenses, costs, and taxes from the revenue. This figure is a clear indicator of BB Biotech's financial health, operational efficiency, and profitability. Higher profit margins signify better cost management and income generation capabilities.
Year-to-Year Comparison
Evaluating BB Biotech's profit on a yearly basis can offer significant insights into its financial growth, stability, and trends. A consistent increase in profit suggests improved operational efficiency, cost management, or increased revenue, while a decrease may indicate rising costs, declining sales, or operational challenges.
Impact on Investments
BB Biotech's profit figures are critical for investors who are aiming to understand the company's financial standing and future growth prospects. Increased profits often lead to higher stock valuations, boosting investor confidence and attracting more investments.
Interpreting Profit Fluctuations
When BB Biotech’s profit increases, it often indicates enhanced operational efficiency or increased sales. In contrast, a decline in profit can signal operational inefficiencies, increased costs, or competitive pressures, necessitating strategic interventions to boost profitability.
Frequently Asked Questions about BB Biotech stock
How has the profit developed compared to last year?
The profit has increased by -194.72% compared to last year fallen
What impact do the earnings have on the shareholders?
An increase in earnings is usually seen as a positive indicator for shareholders as it means that the company is generating profits.
How does BB Biotech publish its earnings?
BB Biotech publishes its earnings in the form of quarterly or annual reports.
Which financial indicators are included in the quarterly or annual reports?
The quarterly or annual reports contain information about sales and profit, cash flow, balance sheet, and other fundamentals.
Why is it important for investors to know the earnings of BB Biotech?
The profits of BB Biotech are an important indicator of the financial health of the company and can help investors decide whether they want to invest in the company or not.
How can one learn more about the earnings of BB Biotech?
You can learn more about the earnings of BB Biotech by reviewing the quarterly or annual reports or following the company presentations.
How much dividend does BB Biotech pay?
Over the past 12 months, BB Biotech paid a dividend of 2.85 CHF . This corresponds to a dividend yield of about 7.67 %. For the coming 12 months, BB Biotech is expected to pay a dividend of 2.57 CHF.
What is the dividend yield of BB Biotech?
The current dividend yield of BB Biotech is 7.67 %.
When does BB Biotech pay dividends?
BB Biotech pays a quarterly dividend. This is distributed in the months of April, April, April, April.
How secure is the dividend of BB Biotech?
BB Biotech paid dividends every year for the past 14 years.
What is the dividend of BB Biotech?
For the upcoming 12 months, dividends amounting to 2.57 CHF are expected. This corresponds to a dividend yield of 6.91 %.
In which sector is BB Biotech located?
BB Biotech is assigned to the '-' sector.
Wann musste ich die Aktien von BB Biotech kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of BB Biotech from 3/27/2024 amounting to 2 CHF, you needed to have the stock in your portfolio before the ex-date on 3/25/2024.
When did BB Biotech pay the last dividend?
The last dividend was paid out on 3/27/2024.
What was the dividend of BB Biotech in the year 2023?
In the year 2023, BB Biotech distributed 3.85 CHF as dividends.
In which currency does BB Biotech pay out the dividend?
The dividends of BB Biotech are distributed in CHF.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
The BB Biotech stock can be added to a savings plan with the following providers: ING
Andere Kennzahlen von BB Biotech
Our stock analysis for BB Biotech Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of BB Biotech Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.